Pfizer Independent Medical Education Grant Request for Proposals: Clinical Data Updates on Long Term Outcomes and Practical Therapy Management Strategies in First-line ALK-positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Pfizer funds education projects to improve healthcare professionals’ knowledge and management of ALK-positive metastatic NSCLC, emphasizing recent clinical data and community oncology practices.
Funder: Pfizer Inc.
Due Dates: July 15, 2026 (Submission Deadline; full application due by 23:59 EST)
Funding Amounts: Up to $250,000 per project; maximum project duration is 1 year; 2–3 proposals will be funded.
Summary: Supports educational projects to advance healthcare professional knowledge and practical management of ALK-positive metastatic NSCLC, with a focus on recent clinical data and community oncology.
Key Information: Only U.S.-based organizations are eligible; clinical research projects are not supported.
Description
This grant opportunity from Pfizer Inc. seeks proposals for independent medical education projects aimed at improving the knowledge and competence of healthcare professionals in the diagnosis, treatment, and management of ALK-positive metastatic non-small cell lung cancer (NSCLC). The focus is on disseminating the latest clinical data and practical therapy management strategies—especially those relevant to community oncology settings. Projects should address educational gaps, optimize ALK inhibitor-based therapy (including adverse event management), and foster collaboration between academic experts and community oncologists. Innovative, peer-to-peer, and digital education formats are encouraged, as well as multidisciplinary approaches and patient education regarding biomarker testing. Clinical research or studies evaluating therapeutic/diagnostic efficacy are not eligible.
